259 related articles for article (PubMed ID: 24556918)
1. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
[TBL] [Abstract][Full Text] [Related]
2. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity.
Köpper F; Bierwirth C; Schön M; Kunze M; Elvers I; Kranz D; Saini P; Menon MB; Walter D; Sørensen CS; Gaestel M; Helleday T; Schön MP; Dobbelstein M
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16856-61. PubMed ID: 24082115
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Li Y; Köpper F; Dobbelstein M
Cancer Lett; 2018 Aug; 428():45-54. PubMed ID: 29704518
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
Nakashima M; Adachi S; Yasuda I; Yamauchi T; Kawaguchi J; Itani M; Yoshioka T; Matsushima-Nishiwaki R; Hirose Y; Kozawa O; Moriwaki H
Cancer Lett; 2011 Dec; 313(2):218-25. PubMed ID: 21999932
[TBL] [Abstract][Full Text] [Related]
6. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
Ewald B; Sampath D; Plunkett W
Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
[TBL] [Abstract][Full Text] [Related]
7. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
[TBL] [Abstract][Full Text] [Related]
8. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
Duong HQ; Hong YB; Kim JS; Lee HS; Yi YW; Kim YJ; Wang A; Zhao W; Cho CH; Seong YS; Bae I
J Cell Mol Med; 2013 Oct; 17(10):1261-70. PubMed ID: 23855452
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
12. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Azorsa DO; Gonzales IM; Basu GD; Choudhary A; Arora S; Bisanz KM; Kiefer JA; Henderson MC; Trent JM; Von Hoff DD; Mousses S
J Transl Med; 2009 Jun; 7():43. PubMed ID: 19519883
[TBL] [Abstract][Full Text] [Related]
13. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Bhattacharjee V; Zhou Y; Yen TJ
Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
[TBL] [Abstract][Full Text] [Related]
14. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Fryer RA; Barlett B; Galustian C; Dalgleish AG
Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
17. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
Guo Q; Chen Y; Wu Y
Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
[TBL] [Abstract][Full Text] [Related]
18. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
19. Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Bu HQ; Luo J; Chen H; Zhang JH; Li HH; Guo HC; Wang ZH; Lin SZ
Int J Oncol; 2012 Sep; 41(3):949-58. PubMed ID: 22710877
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Shimizu K; Nishiyama T; Hori Y
Pancreas; 2017 Feb; 46(2):268-275. PubMed ID: 28060183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
